Multiple sclerosis: An immunologic perspective

Physical Medicine and Rehabilitation Clinics of North America

Volumn 16, Issue 2, 2005, Pages 351-358

  Cui, Jimmy Y ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; CYTOKINE; GLATIRAMER; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; THYMOCYTE ANTIBODY;

CELLULAR IMMUNITY; DRUG ACTIVITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MACROPHAGE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANTIBODY FORMATION; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MULTIPLE SCLEROSIS;

EID: 18944377104     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmr.2005.01.008     Document Type: Review

References (20)

1. B.D. Trapp, J. Peterson, and R.M. Ransohoff Axonal transection in the lesions of multiple sclerosis New Engl J Med 338 1998 278 285
2. J. Al-Omaishi, R. Bashir, and H.E. Gendelman The cellular immunology of multiple sclerosis J Leukoc Biol 65 1999 444 452
3. M. Allegretta, J.A. Nicklas, and S. Sriram T cells responsive to myelin basic protein in patient with multiple sclerosis Science 247 1990 718 721
4. J. Zhang, S. Markovic-plese, and B. Lacet Increased frequency of interleukin 2- responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis J Exp Med 179 1994 973 984
5. C. Stadelmann, M. Kerschensteiner, and T. Misgeld BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125 Pt 1 2002 75 85
6. R. Hohlfeld, M. Kerschensteiner, and C. Stadelmann The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis J Neuroimmunol 107 2 2000 161 166
7. J.P. Antel, and A. Bar-Or Do myelin-directed antibodies predict multiple sclerosis New Engl J Med 249 2003 107 109
8. Committee on MS Institute of Medicine: Clinical and biological features J.E. Joy R.B. Johnston Jr. Multiple sclerosis: current status and strategies for the future 2001 National Academy Press Washington, DC 29 114
9. R. Taylor Immunologic aspects of multiple sclerosis Phys Med Rehabil Clin N Am 9 1998 525 536
10. A. Prat, K. Biernacki, and J.F. Lavoie Migration of multiple sclerosis lymphocytes through brain endothelium Arch Neurol 59 3 2002 391 397
11. H.P. Hartung, R. Gonsette, and N. Konig Mitxoantrone in progressive MS: a placebo-controlled, double-blind, randomized, multicentre trial Lancet 360 2002 2018 2025
12. G. Kraft, J. Bowen, and J. Cui Clinical application of autologous stem cell transplantation in severe MS treated with high-dose immunosuppressive therapy Neurology 58 Suppl 3 2002 A166
13. V.W. Yong Differential mechanisms of action of interferon beta and glatiramer acetate in MS Neurology 59 2002 802 808
14. O. Neuhaus, C. Farina, and H. Wekerle Mechanism of action of glatiramer acetate in multiple sclerosis Neurology 56 2001 702 708
15. M. Chen, R.M. Malenzuela, and S. Dhib-Jalbut Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor J Neurol Sci 215 2003 37 44
16. P.S. Sorensen, C. Ross, and K.M. Clemmesen Clinical importance of neutralizing antibodies against interferon beta in patients with RR MS Lancet 362 2003 1184 1191
17. A. Miller, D. Bourdette, and J.A. Cohen The significance of neutralizing antibodies in patients treated with interferon Continuum lifelong learning in neurology: Multiple sclerosis 5 5 1999 107 119
18. G.P.A. Rice, B. Paszner, and J. Oger The evolution of neutralizing antibodies in MS patients treated with interferon beta-1b Neurology 52 1999 1277 1279
19. The IFNB Multiple Sclerosis Study Group and the University of British Colombia MS/MRI Analysis Group Neutralizing antibodies during treatment of MS with interferon beta-1b: experience during the first 3 years Neurology 47 1996 889 894
20. D. Teitelbaum, T. Brenner, and O. Abramsky Antibodies to glatiramer acetate do not interfere with its biological function and therapeutic efficacy Mult Scler 9 2003 592 599